Top

Published in:

Open Access 01-12-2018 | Original Paper

miR-21 expression analysis in budding colon cancer cells by confocal slide scanning microscopy

Authors: Kirsten Nguyen Knudsen, Jan Lindebjerg, Alexandra Kalmár, Béla Molnár, Flemming Brandt Sørensen, Torben Frøstrup Hansen, Boye Schnack Nielsen

Published in: Clinical & Experimental Metastasis | Issue 8/2018

Abstract

MicroRNA-21 (miR-21) expression in stromal fibroblastic cells in colorectal cancer is well-documented, whereas miR-21 expression in tumor budding cells (TBCs) is poorly described. TBCs are locally invasive carcinoma cells with increased metastatic properties and characteristics of epithelial to mesenchymal transition. This study was conducted to better characterize the expression of miR-21 in TBCs. First, chromogenic miR-21 in situ hybridization (ISH) staining was performed in 58 colon adenocarcinomas with evident TBCs. Then, to obtain unambiguous identification of miR-21 in the TBCs, twenty cases were selected for an additional multiplex fluorescence analysis combining miR-21 ISH with cytokeratin and laminin-5γ2 immunofluorescence. Employing confocal slide scanning microscopy, comprehensive digital images of the invasive front (10–40 mm²) were obtained from 16 of the 20 cases, and miR-21 expression was evaluated in cytokeratin-positive TBCs. The high resolution of the confocal digital slide images allowed a detailed examination of the confocal stacks of the multiplex-stained tissue sections. The cases with the highest fraction of miR-21 positive TBCs were all stage III cancers defined by the presence of regional lymph node metastasis. Some of the miR-21 positive TBCs were also laminin-5γ2 positive. The confocal image stacks also revealed that some TBCs were actually directly connected to malignant glands. In conclusion, miR-21 expression was unambiguously identified in TBCs by evaluation of digital slides obtained by confocal slide scanning microscopy. In addition, the digital confocal slides provided a more detailed understanding of local cancer cell invasion by allowing evaluation of the cell structures in three dimensions.

Available only for authorised users

Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6(5):376–385CrossRef

Reddy KB (2015) MicroRNA (miRNA) in cancer. Cancer Cell Int 15:38CrossRef

Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033CrossRef

Slaby O et al (2007) Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72(5–6):397–402CrossRef

Schetter AJ et al (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4):425–436CrossRef

Volinia S et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257–2261CrossRef

Krichevsky AM, Gabriely G (2009) miR-21: a small multi-faceted RNA. J Cell Mol Med 13(1):39–53CrossRef

Nielsen BS et al (2011) High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28(1):27–38CrossRef

Kjaer-Frifeldt S et al (2012) The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer 107(7):1169–1174CrossRef

10.

Kang WK et al (2015) Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse. BMC Gastroenterol 15:2CrossRef

11.

Bullock MD et al (2015) Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget 6(9):7262–7279CrossRef

12.

Zlobec I, Lugli A (2010) Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 1(7):651–661PubMedPubMedCentral

13.

Dawson H, Lugli A (2015) Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne) 2:11

14.

Brabletz T et al (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98(18):10356–10361CrossRef

15.

Shinto E et al (2005) Prognostic implication of laminin-5 gamma 2 chain expression in the invasive front of colorectal cancers, disclosed by area-specific four-point tissue microarrays. Lab Investig 85(2):257–266CrossRef

16.

Kajiwara Y et al (2011) Expression of l1 cell adhesion molecule and morphologic features at the invasive front of colorectal cancer. Am J Clin Pathol 136(1):138–144CrossRef

17.

Brabletz T et al (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194(10):701–704CrossRef

18.

Ohtsuki K et al (2008) Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res 28(3B):1831–1836PubMed

19.

Koelzer VH et al (2015) Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch 466(5):485–493CrossRef

20.

Hase K et al (1993) Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 36(7):627–635CrossRef

21.

Ueno H et al (2004) A new prognostic staging system for rectal cancer. Ann Surg 240(5):832–839CrossRef

22.

Wang LM et al (2009) Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 33(1):134–141CrossRef

23.

Rogers AC et al (2016) Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer 115(7):831–840CrossRef

24.

Mitrovic B et al (2012) Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol 25(10):1315–1325CrossRef

25.

Lugli A et al (2017) Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 30 9), pp 1299–1311CrossRef

26.

Jorgensen S et al (2010) Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 52(4):375–381CrossRef

27.

Knudsen KN et al (2015) microRNA-17 Is the most up-regulated member of the miR-17-92 cluster during early colon cancer evolution. PLoS One 10(10):e0140503CrossRef

28.

Sempere LF (2014) Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine? Expert Rev Mol Diagn 14(7):853–869CrossRef

29.

Liu A et al (2009) MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol 2(6):519–527PubMedPubMedCentral

30.

Siebolts U et al (2009) Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol 62(1):84–88CrossRef

31.

Viegas MS et al (2007) An improved and cost-effective methodology for the reduction of autofluorescence in direct immunofluorescence studies on formalin-fixed paraffin-embedded tissues. Eur J Histochem 51(1):59–66PubMed

32.

Langhorst MF, Schaffer J, Goetze B (2009) Structure brings clarity: structured illumination microscopy in cell biology. Biotechnol J 4(6):858–865CrossRef

33.

Neil MA, Juskaitis R, Wilson T (1997) Method of obtaining optical sectioning by using structured light in a conventional microscope. Opt Lett 22(24):1905–1907CrossRef

34.

Knudsen KN et al (2017) MicroRNA-200b is downregulated in colon cancer budding cells. PLoS One 12(5):e0178564CrossRef

35.

Karamitopoulou E et al (2013) Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol 26(2):295–301CrossRef

36.

Nielsen BS, Holmstrom K (2013) Combined microRNA in situ hybridization and immunohistochemical detection of protein markers. Methods Mol Biol 986:353–365CrossRef

37.

Pirici D et al (2009) Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtype. J Histochem Cytochem 57(6):567–575CrossRef

38.

Baran B et al (2018) Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res 11(4):264–273CrossRef

39.

Pyke C et al (1995) Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 55(18):4132–4139PubMed

40.

Sordat I et al (2000) Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer 88(5):708–717CrossRef

41.

Cottonham CL, Kaneko S, Xu L (2010) miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 285(46):35293–35302CrossRef

42.

Zhang D, Xie L, Jin Y (2015) In situ detection of MicroRNAs: the art of MicroRNA research in human diseases. J Cytol Histol 1(Suppl 3):013

43.

Stenvold H et al (2014) High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome. BMC Clin Pathol 14(1):9CrossRef

44.

Sempere LF et al (2010) Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 16(16):4246–4255CrossRef

45.

Nielsen BS et al (2014) miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Front Oncol 4:207CrossRef

46.

Sempere LF et al (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67(24):11612–11620CrossRef

47.

Koelzer VH, Zlobec I, Lugli A (2016) Tumor budding in colorectal cancer—ready for diagnostic practice? Hum Pathol 47(1):4–19CrossRef

48.

Foldes-Papp Z, Demel U, Tilz GP (2003) Laser scanning confocal fluorescence microscopy: an overview. Int Immunopharmacol 3(13–14):1715–1729CrossRef

49.

Bronsert P et al (2014) Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. J Pathol 234(3):410–422CrossRef

50.

Grigore AD et al (2016) Tumor budding: the name is EMT. Partial EMT. J Clin Med 5:5CrossRef

51.

Han M et al (2012) Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem 363(1–2):427–436CrossRef

52.

Yue X et al (2016) Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget 7(4):3777–3790CrossRef

53.

Ferraro A et al (2014) Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGBeta4-PDCD4) as predictor of metastatic tumor potential. Epigenetics 9(1):129–141CrossRef

54.

Li C et al (2016) MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression. BMC Cancer 16:605CrossRef

55.

Nedaeinia R et al (2016) Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer Gene Ther 23(8):246–253CrossRef

56.

Ortega FG et al (2015) miRNA in situ hybridization in circulating tumor cells-MishCTC. Sci Rep 5:9207CrossRef

57.

Leone E et al (2013) Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 19(8):2096–2106CrossRef

58.

Lee TJ et al (2017) RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of oncogenic miR-21. Mol Ther 25(7):1544–1555CrossRef

Title: miR-21 expression analysis in budding colon cancer cells by confocal slide scanning microscopy
Authors: Kirsten Nguyen Knudsen
Jan Lindebjerg
Alexandra Kalmár
Béla Molnár
Flemming Brandt Sørensen
Torben Frøstrup Hansen
Boye Schnack Nielsen
Publication date: 01-12-2018
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 8/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9945-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2018

Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)

Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center

Role of simvastatin in tumor lymphangiogenesis and lymph node metastasis

Efficacy and safety of 3D-conformal half body irradiation in patients with multiple bone metastases

Radiotherapy in palliation of thoracic tumors: a phase I–II study (SHARON project)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer